Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM PRESERVATIVE FREE versus PRADAXA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM PRESERVATIVE FREE versus PRADAXA.
HEPARIN SODIUM PRESERVATIVE FREE vs PRADAXA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III (ATIII), causing a conformational change that accelerates the inactivation of thrombin (factor IIa) and factor Xa, as well as factors IXa, XIa, and XIIa. This inhibits clot formation and propagation.
Direct thrombin inhibitor; binds reversibly to the active site of thrombin, preventing fibrinogen cleavage and subsequent thrombus formation.
Initial bolus of 80 units/kg IV, followed by continuous infusion at 18 units/kg/hour IV; adjusted to maintain aPTT of 1.5-2.5 times control.
150 mg orally twice daily; for patients with CrCl 15-30 mL/min, 75 mg orally twice daily.
None Documented
None Documented
Terminal half-life is 0.5–2.5 hours (mean ~1.5 h) after IV administration; dose-dependent due to saturable clearance. At therapeutic doses, half-life averages 1–2 hours.
12–17 hours (terminal); prolonged to 18–35 hours in severe renal impairment (CrCl <30 mL/min); supports twice-daily dosing
Primarily renal; small amounts in urine as unchanged drug and metabolites. Biliary/fecal elimination is negligible (<5%).
Renal (80% unchanged); fecal/biliary (20% as inactive metabolites via P-glycoprotein-mediated secretion)
Category A/B
Category C
Anticoagulant
Anticoagulant